Background: There are over 30,000 patients with cystic fibrosis and about 80,000 diagnosed each year with pancreatitis in the United States. Pancreatic enzyme products (PEPs) containing the active ingredient pancrelipase, a mixture of the digestive enzymes amylase, lipase, and protease are frequently prescribed to both groups. Case reports of fibrosing colonopathy with pancreatic enzyme supplements have been reported in children with cystic fibrosis and rarely in adults. We sought to identify adverse events affecting small and large intestines with the use of pancreatic enzyme supplements reported to a pharmacovigilance database using the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: More than 3.1 million files between January 2003 and June 2012 were downloaded from the FAERS and analyzed using SPSS 20 (IBM Co. Armonk, NY). They were queried for Primary Suspect (PS) reports of adverse events with PEPs, using both trade and generic names. All approved indications were used, and the Medical Dictionary for Regulatory Activities (version 15.1 September 2012) was used to identify all primary and lower-level search terms. All reactions, after querying for indication and drug, were then hand searched for intestinal adverse events. Results: There were 114 PS cases (table 1) of small and large intestinal adverse events identified with PEPs. A total of 38 cases were associated with cystic fibrosis, 27 with pancreatitis, and 49 associated with unspecified pancreatic indications (pancreatic insufficiency, neoplasm of the pancreas, pancreatic operations, pancreatic disorders not otherwise specified). A majority of intestinal adverse events were found in females (52.2%). Average age of cases by indication of usage was 16±14 years for those with cystic fibrosis, 64±18 years for those with pancreatitis and 52±28 years for those with unspecified pancreatic indications. Diarrhea was the most common adverse reaction. We identified 17 cases of small or large intestinal obstruction. Three of the 17 obstruction cases had a concomitant medication which may have led to the obstruction (1 on meloxicam and 1 on loperamide leading to an intestinal obstruction, and 1 on oxycodone leading to a colonic obstruction). This results in an intestinal obstruction rate of 1.47 cases per year and a colonic obstruction rate of 0.32 cases a year, within the context of cases reported to the FDA. Conclusion: Diarrhea is most likely related to the underlying disease state. Serious complications such as small and large intestinal obstructions are rarely reported with PEPs in context of the large number of patients who are prescribed these drugs. More research is warranted to identify the at-risk patient population for serious intestinal adverse events associated with PEPs. Table 1: Small and large intestinal adverse reactions associated with pancrelipase tablets and delayed release capsules